Effect of prior hypomethylating agent (HMA) use on clinical outcome of patients (Pts) with secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndrome (MDS) when treated with standard induction chemotherapy (7+3).
Mayo Clinic
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e18041-e18041
10.1200/jco.2015.33.15_suppl.e18041